WO2015165980A3 - Treatment and prevention of alzheimer's disease (ad) - Google Patents

Treatment and prevention of alzheimer's disease (ad) Download PDF

Info

Publication number
WO2015165980A3
WO2015165980A3 PCT/EP2015/059364 EP2015059364W WO2015165980A3 WO 2015165980 A3 WO2015165980 A3 WO 2015165980A3 EP 2015059364 W EP2015059364 W EP 2015059364W WO 2015165980 A3 WO2015165980 A3 WO 2015165980A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
alzheimer
disease
monocyte
Prior art date
Application number
PCT/EP2015/059364
Other languages
French (fr)
Other versions
WO2015165980A2 (en
Inventor
Markus Mandler
Radmila Santic
Achim Schneeberger
Frank Mattner
Walter Schmidt
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of WO2015165980A2 publication Critical patent/WO2015165980A2/en
Publication of WO2015165980A3 publication Critical patent/WO2015165980A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a monocyte inducing agent and/or a monocyte activating agent and/or a monocyte recruiting agent for use in the treatment and prevention of AD.
PCT/EP2015/059364 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad) WO2015165980A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14166386.4 2014-04-29
EP14166355 2014-04-29
EP14166355.9 2014-04-29
EP14166386 2014-04-29

Publications (2)

Publication Number Publication Date
WO2015165980A2 WO2015165980A2 (en) 2015-11-05
WO2015165980A3 true WO2015165980A3 (en) 2016-02-04

Family

ID=53039900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/059364 WO2015165980A2 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Country Status (1)

Country Link
WO (1) WO2015165980A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649335B1 (en) * 2016-03-30 2017-05-16 Baylor University Intravenous administration of an oxygen-enabled fluid
CN111727260A (en) * 2019-10-15 2020-09-29 湖南乾康科技有限公司 Application of intermediate monocyte in preparation of drugs for diagnosing and predicting AD
CN117122612B (en) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 Application of peripheral blood mononuclear cells in preparation of medicines for treating/preventing Alzheimer disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012055981A1 (en) * 2010-10-27 2012-05-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions and methods for treating neurologic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012055981A1 (en) * 2010-10-27 2012-05-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions and methods for treating neurologic disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHANNA MAGGA ET AL: "Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer's disease", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 16, no. 5, 26 April 2012 (2012-04-26), pages 1060 - 1073, XP055143513, ISSN: 1582-1838, DOI: 10.1111/j.1582-4934.2011.01390.x *
LEBSON L A ET AL: "Monocyte gene therapy in Alzheimer's disease APP+PS1 transgenic mice", CELL TRANSPLANTATION, COGNIZANT COMMUNICATION CORP, US, vol. 17, no. 4, 2008, pages 470 - 471, XP009180477, ISSN: 0963-6897 *
TARJA MALM ET AL: "The role and therapeutic potential of monocytic cells in Alzheimer's disease", GLIA, 12 February 2010 (2010-02-12), pages NA - NA, XP055143504, ISSN: 0894-1491, DOI: 10.1002/glia.20973 *

Also Published As

Publication number Publication date
WO2015165980A2 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
IL271492A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
PL3577135T3 (en) A pharmaceutical composition for use in the treatment or prevention of c5-related diseases
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
IL254142B (en) Tradipitant for use in the treatment of a tradipitant-responsive disease or condition
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3429598A4 (en) Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
EP3185862A4 (en) Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
GB2564459B (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
EP3427731A4 (en) Ameliorating agent for female-specific physical and/or mental unpleasant symptom
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
EP3398614A4 (en) Agent for preventing and/or treating alzheimer's disease
WO2015165980A3 (en) Treatment and prevention of alzheimer's disease (ad)
HK1243709A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
WO2015106108A3 (en) Novel functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy
EP3137097C0 (en) Treatment and prevention of alzheimer's disease (ad)
PL3166660T3 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
CY1119674T1 (en) Alzheimer's Disease Treatment and Prevention (AD)
HUE055732T2 (en) Novel tetrazole compounds and their use in the treatment of tuberculosis
EP3162377A4 (en) Use of -asarone in preparing drugs for preventing and treating alzheimer's disease
PL3413870T3 (en) Igmesine for use in the treatment of alzheimer's disease
PT3137094T (en) Treatment and prevention of alzheimer's disease (ad)
IL274838A (en) Use of mir101 or mir128 in the treatment of seizure disorders
ITUA20163037A1 (en) Formulations for use in the treatment or prevention of urological disorders
EP3646872A4 (en) Agent for preventing and/or treating alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15720064

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15720064

Country of ref document: EP

Kind code of ref document: A2